Form 4: Ionis CSO Granted 19,350 Stock Options

Ionis Pharmaceuticals' EVP and Chief Scientific Officer, C. Frank Bennett, was granted 19,350 non-qualified stock options with an exercise price of $79.67.

Summary

• C. Frank Bennett, Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals, Inc., was granted 19,350 non-qualified stock options.
• The options have an exercise price of $79.67 per share.
• The grant was made on January 2, 2026, under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• Following this transaction, Bennett beneficially owns 19,350 derivative securities.
• The options will vest over time, with 25% becoming exercisable on January 2, 2027, and the remainder vesting in 36 equal monthly installments over the subsequent three years.
• The options have an expiration date of January 1, 2036.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal for management alignment and retention, though it introduces potential future dilution. It's a standard corporate action, hence a moderately positive score.

Positives

• The grant of stock options to a key executive like the Chief Scientific Officer aligns management's interests with long-term shareholder value.
• Equity incentives are a common tool for retaining top talent in the highly competitive biotechnology and pharmaceutical sectors.

Negatives

• The issuance of new stock options could lead to potential future dilution for existing shareholders if the options are exercised.

Risks

• The value of the stock options is dependent on the future performance of Ionis Pharmaceuticals' stock price, which is subject to market volatility and company-specific factors.
• The vesting schedule ties the executive's compensation to long-term performance, but there is no guarantee of stock price appreciation.

Future Outlook

The vesting schedule for the stock options indicates a long-term incentive structure for the Chief Scientific Officer, aligning their future compensation with the company's sustained performance over the next several years.

Industry Context

Executive stock option grants are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key scientific and management personnel. These grants are crucial for companies like Ionis, which rely heavily on long-term research and development cycles, to ensure leadership commitment.

Comparison to Industry Standards

• The grant of stock options to a Chief Scientific Officer is a common form of executive compensation in the biotech sector, comparable to practices at companies like Biogen, Gilead Sciences, or Amgen, where equity incentives are a significant component of total compensation.
• The vesting schedule, with an initial cliff and subsequent monthly installments over three years, is a typical structure designed to encourage long-term retention and performance, aligning with industry benchmarks for executive equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from incentivized executive performance and retention.
• Employees: May view this as a positive sign of executive commitment and a standard practice for rewarding leadership.

Next Steps

• The stock options will begin vesting on January 2, 2027, with subsequent monthly vesting over the following three years.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Stock Options, Executive Compensation, Form 4, Equity Incentive Plan, Biotechnology, Pharmaceuticals